Biopharma
GSK halts camlipixant development after mixed Phase III results in chronic cough trials
The global biopharma company said the CALM-1 study achieved its primary endpoint
- By IPP Bureau
| July 19, 2026
GSK has ended further development of camlipixant as a treatment for refractory chronic cough (RCC) after its Phase III CALM programme delivered mixed results, with one trial meeting its main goal but the second failing to show a statistically significant benefit.
The global biopharma company said the CALM-1 study achieved its primary endpoint, with camlipixant 50mg twice daily producing a statistically significant reduction in 24-hour cough frequency compared with placebo at week 12.
However, the companion CALM-2 trial failed to meet the same primary endpoint at week 24. The lower 25mg twice-daily dose also failed to demonstrate statistically significant results in either study, while key secondary measures — including the Chronic Cough Diary (CCD) assessment — did not reach required thresholds.
Despite the mixed findings, GSK reported that safety results remained consistent across both trials, with treatment-related adverse events showing similar overall incidence and severity among patients receiving camlipixant and placebo.
“Based on the aggregate data, the limited efficacy demonstrated is unlikely to transform patient care,” GSK said, adding that it has decided “not to progress further development of camlipixant in RCC.”
The company said results from the CALM Phase III programme will be submitted for future scientific presentation and publication to help advance understanding of refractory chronic cough, a condition described as complex, under-recognised and lacking effective treatment options.
